Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 9/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 7/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016841 | 0.97 | ITGB1 (0.31) | ITGA4ITGB1ITGB7RAF1BRAF | |
| SCHEMBL22017162 | 0.94 | CNR2 (0.32) | RAF1BRAFFPR2 | |
| SCHEMBL22017151 | 0.90 | ITGB1 (0.30) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21955100 | 0.87 | ITGB1 (0.44) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21955101 | 0.87 | ITGB1 (0.44) | ITGA4ITGB1ITGB7 | |
| SCHEMBL21955104 | 0.87 | ITGB1 (0.44) | ITGA4ITGB1ITGB7 | |
| SCHEMBL22016549 | 0.87 | ITGB1 (0.33) | ITGA4ITGB1ITGB7CPB2PIK3CA | |
| SCHEMBL22016719 | 0.85 | ITGB1 (0.35) | ITGA4ITGB1ITGB7RAF1BRAF | |
| SCHEMBL22017402 | 0.84 | PIK3CA (0.31) | ITGA4ITGB1ITGB7PIK3CA | |
| SCHEMBL22016539 | 0.82 | ITGB1 (0.32) | ITGA4ITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 4/4885ITGB7 1/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 4/4885ITGB7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.